# Benjamin Lund

> Benjamin Lund is a venture - series unknown investor at Bain Capital Life Sciences backing Health Care. See 3 investments, check sizes, portfolio and contact…

- Type: Angel Investor
- Fund: [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences)
- Total investments: 3
- Last investment: Aug 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/benjamin-lund-4982ab79

Benjamin Lund is a venture - series unknown investor at Bain Capital Life Sciences focused on Health Care and Biotechnology. Benjamin Lund is the Partner at Bain Capital. He attended Princeton University.

## Contacts

5 contacts available for Benjamin Lund: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/benjamin-lund-f1f9?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Biopharma | 1 | 33% |
| Neuroscience | 1 | 33% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 2 | 67% |
| Series A | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Longeviti | Longeviti was founded in 2016 by a team of leading medical device industry executives, neurosurgeons, plastic surgeons, and biomedical engineers. The team collaborates closely with industry and academia to develop and commercialize implantable neurosurgical devices. | $10M | Venture - Series Unknown | Aug 07, 2025 |  |
| Pillar Biosciences | Pillar Biosciences is prized with its patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which achieves high sensitivity and specificity with clinical samples. The platform provides a fast, simple and affordable targeted sequencing method for NGS-based oncology testing. The start-up has also released itsbeta version of Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel to cancer centers and clinical testing companies in the US and China for validation studies.The company was founded in 2014 and is headquartered in Natick, Massachusetts. | $34.5M | Venture - Series Unknown | May 27, 2025 |  |
| Interius BioTherapeutics | Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $76M | Series A | May 18, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 1 deal together
- [BrightEdge Fund](https://shizune.co/investors/profile/brightedge-fund) — VC Fund, 1 deal together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 1 deal together
- [Fairmount Funds Management](https://shizune.co/investors/profile/fairmount-funds-management) — VC Fund, 1 deal together
- [Illumina](https://shizune.co/investors/profile/illumina) — VC Fund, 1 deal together
- [Knollwood Investment Advisory](https://shizune.co/investors/profile/knollwood-investment-advisory) — VC Fund, 1 deal together

## About Bain Capital Life Sciences

VC Fund · Boston, United States

Bain Capital Life Sciences specializes in buyouts, inflexion capital, growth capital, turnaround investments, and private equity. It invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that both drive medical innovation across the value chain and enablethat innovation to improve the lives of patients with unmet medical needs. The differentiated skillset of the Bain Capital Life Sciences team enables it to deliver targeted capital and value-added strategic support to companies around critical phases of growth and inflexions in value.

5 contacts available at Bain Capital Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Adam Koppel | Managing Director | https://shizune.co/investors/profile/adam-koppel |
| Andrew Hack | Managing Director | — |
| Benjamin Lund | Partner | — |
| Coleman Mark | Founder | — |
| Eric Kriss | Founder | — |

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Benjamin Lund invest in?

Benjamin Lund invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Benjamin Lund?

Public channels for Benjamin Lund include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Benjamin Lund last invest?

The most recent investment recorded for Benjamin Lund closed in Aug 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co